OmicsBank Raises $2.25M for Clinical Data Infrastructure

OmicsBank is financing a difficult layer of clinical AI: turning the fragmented records already inside hospitals into linked, governed data that drug developers and model builders can actually use. The San Francisco company announced $2.25M in seed funding from Redesign Health on August 25, 2026.

The capital will support expansion across U.S. health systems, pharmaceutical and biotechnology companies, contract research organizations, and AI developers. OmicsBank also plans to grow its hospital network in the Middle East and Southeast Asia and build GPU-enabled research environments for model training, reinforcement learning, biomarker discovery, and real-world evidence.

What OmicsBank Raised

The financing is a $2.25M seed investment from Redesign Health, a healthcare venture and applied-technology firm. OmicsBank's announcement identifies Redesign Health as the source of the seed capital and does not disclose additional investors, valuation, ownership, or revenue terms.

Orbit Ventures led an earlier pre-seed round in 2025, but the amount of that financing was not disclosed in the primary materials reviewed for this article. That distinction matters because the newest $2.25M should not be presented as OmicsBank's verified lifetime funding total.

OmicsBank was founded in 2025 by Sumit Sinha and Vijay Goel. Sinha is the company's co-founder and CEO, while Goel is identified as a co-founder. No current CTO was confirmed in the available primary sources, so attaching that title to either founder would turn a sparse leadership record into a guess.

The Product Lives Inside Hospital Infrastructure

Hospital records are fragmented by design and history. Notes live in electronic health records, imaging in PACS, laboratory results in separate systems, pathology on slides and image servers, and genomic files in specialized repositories. A patient can move through all of those systems without the institution producing one standardized longitudinal record that a research team or model can query safely.

OmicsBank deploys software within the hospital environment to ingest, structure, link, and de-identify those records. The company says its stack maps data to standards including FHIR and OMOP CDM and connects clinical events with imaging, pathology, pharmacy, and multi-omics data. It also says consent state, transformation lineage, and source attribution travel with the data, while on-premise and air-gapped deployment options help institutions keep control of sensitive records.

That architecture makes governance part of the product rather than an export-time promise. It also makes hospital trust a commercial dependency. A technically capable platform still has to persuade each institution that data access, patient privacy, research approval, and cross-border rules will remain enforceable after the next customer or geography joins the network.

Company-Reported Scale and the Representation Gap

OmicsBank says its technology operates across more than 90 hospitals and diagnostic labs in Asia. Its current website lists 90 hospital units, 10 diagnostic labs, more than 12M patient records, 30M+ imaging studies, 6M+ pathology slides, 500K+ biospecimens, and 300K+ sequencing files across 17 therapeutic areas. These are company-reported network figures, not independently audited measures of customer adoption or research outcomes.

The company's fundraising argument is tied to a real scientific imbalance. A peer-reviewed review of South Asian participation in genetic research found that South Asians represent about 25% of the global population but less than 2% of participants in genome-wide association studies. Underrepresentation limits population-specific understanding of disease risk and can weaken how well discoveries generalize beyond the groups represented in the original data.

OmicsBank is trying to make data from underrepresented populations more usable without detaching it from the hospitals and governance systems that produced it. For pharmaceutical and biotechnology teams, the proposition includes research-ready cohorts, biomarker work, clinical development, and real-world evidence. For frontier AI developers, the company offers multimodal data for pre-training, post-training, evaluation, and reinforcement-learning environments.

Why Redesign Health Backed the Founders

Redesign Health's investment case emphasizes operating judgment as much as market size. Neil Patel, the firm's Head of Ventures, said Redesign underwrote Sinha and Goel first and pointed to their experience building five companies between them. The relevant capability is not simply moving fast; it is earning trust from hospitals one institution at a time while building infrastructure across technical and regulatory boundaries.

That is a useful lens for the financing. $2.25M can help OmicsBank add deployments, commercial relationships, and compute environments, but it does not buy automatic access to hospital archives. Institutional agreements, ethics approvals, data quality, consent, security, and provenance remain the work that determines whether the network becomes durable infrastructure or an impressive collection of company-reported scale metrics.

Orbit Ventures' role in the 2025 pre-seed adds continuity to the capital story. Oscar Ramos Moreno, the firm's Managing General Partner, framed the original investment around making medical and pharmaceutical research more representative of emerging-market populations. Redesign Health is now financing the next test: whether that regional data foundation can support U.S. health systems and global drug and AI teams without weakening the governance that made the access possible.

What the Seed Round Changes

The immediate plan is geographic and commercial expansion. OmicsBank intends to add hospital relationships across the U.S., the Middle East, and Southeast Asia, deepen work with pharmaceutical and biotechnology companies, and support AI developers that need clinically grounded multimodal data. GPU-enabled research environments are also meant to let compute move closer to the records when patient-level data cannot leave an institution or country.

The larger market signal is that clinical AI infrastructure is moving upstream from models to data supply chains. A model can be tuned, benchmarked, and replaced. A governed network of longitudinal patient records across hospitals, modalities, diseases, and populations is slower to assemble because the hard parts are institutional, legal, and human as well as technical.

OmicsBank still has to prove data quality, customer outcomes, commercial repeatability, and regulatory durability at greater scale. The company has not disclosed revenue, named customers, valuation, or independently validated performance. The seed round earns it room to test whether representative clinical data can become a defensible platform without treating patient trust as raw material.